Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Director · PRESIDENT AND CEO | February 17, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date February 17, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,657 |
Reported balance
After 2026-02-17 transaction · row 1
1 source rowRow 1 · 2026-02-17 · Tax withholding · Disposed 51 · Balance 1,657 F1: The reporting person is reporting the withholding by the Issuer of an aggregate of 51 shares of common stock in connection with shares that vested on February 15, 2026 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is reporting the withholding by the Issuer of an aggregate of 51 shares of common stock in connection with shares that vested on February 15, 2026 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 18, 2026 21:25 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 51 | $1.10 | $56.10 |
DisclosureSEC source: 0001579988-26-000004 · ownership.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,657 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 51 shares of common stock in connection with shares that vested on February 15, 2026 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:14 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 69,484 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001579988-26-000002 · ownership.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,484 Underlying: Common Stock · 69,484 shares Expires 2036-02-01 F1 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:58 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 75 | $3.69 | $276.75 |
DisclosureSEC source: 0001411690-25-000053 · wk-form4_1748991505.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,708 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 75 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 75 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:45 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 17,449 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001411690-25-000028 · wk-form4_1742337929.xml · derivative · entry 3 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,449 Underlying: Common Stock · 17,449 shares Expires 2035-03-13 F2 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:45 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 198 | $3.47 | $687.06 |
DisclosureSEC source: 0001411690-25-000028 · wk-form4_1742337929.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,783 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 198 shares of common stock in connection with shares that vested on March 14, 2025 pursuant to an PSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the PSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 198 shares of common stock in connection with shares that vested on March 14, 2025 pursuant to an PSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the PSU award. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 23:56 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 51 | $5.73 | $292.23 |
DisclosureSEC source: 0001411690-25-000017 · wk-form4_1740009410.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,981 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 51 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 51 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On January 24, 2025, the common stock of Bionano Genomics, Inc. split 1-for-60, resulting in the reporting person's ownership of 120,428 less shares of common stock (119,934 less shares held directly and 494 less shares held indirectly). F3 · balance_after: Includes 2 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 10, 2024 (As adjusted for the January 2025 Reverse Stock Split). Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:43 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 204,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-24-015621 · form4-06052024_090635.xml · derivative · entry 3 Holmlin R. Erik · CIK 0001579988 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Stock · 204,000 shares Expires 2034-06-02 F4 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:43 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015621 · form4-06052024_090635.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,813 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · shares: The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date. F3 · balance_after: Includes 150 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 9, 2023. Read SEC document |
| February 15, 2024 Filed Mar 5, 2024 22:46 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 3,073 | $1.27 | $3,902.71 |
DisclosureSEC source: 0001415889-24-006809 · form4-03052024_100317.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,663 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 3,073 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 3,073 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On August 4, 2023, the common stock of Bionano Genomics, Inc. split 1-for-10, resulting in the reporting person's ownership of 730,350 less shares of common stock (725,827 less shares held directly and 4,523 less shares held indirectly). F3 · balance_after: Includes 89 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 12, 2023. Read SEC document |
| May 16, 2023 Filed May 16, 2023 22:23 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 15,000 | $0.64 | $9,639.00 |
DisclosureSEC source: 0001411690-23-000032 · wf-form4_168427581326105.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 806,474 F1 · price: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.64160 to $0.643099, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 12, 2023 Filed May 16, 2023 22:18 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 50,141 | $0.66 | $33,093.06 |
DisclosureSEC source: 0001411690-23-000029 · wf-form4_168427549067289.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,474 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 50,141 shares of common stock that vested on May 12, 2023 pursuant to an RSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:23 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 1,400,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-010921 · doc4.xml · derivative · entry 3 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2033-02-14 F3 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2023 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:23 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010921 · doc4.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,615 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes 1,443 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2022 and 1,616 shares acquired under the ESPP on December 10, 2022. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:23 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 50,141 | $1.41 | $70,698.81 |
DisclosureSEC source: 0001209191-22-029457 · doc4.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,556 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 50,141 shares of common stock that vested on May 12, 2022 pursuant to an RSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: Includes 1,804 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2021 and 1,702 shares acquired under the ESPP on December 10, 2021. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 02:05 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 1,400,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-22-010044 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 11:00 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 150 | $3.98 | $597.00 |
DisclosureSEC source: 0001209191-21-067229 · doc4.xml · nonDerivative · entry 3 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Robert Erik Holmlin Traditional IRA Disclosed balance after: 5,025 Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 11:00 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 2,675 | $3.99 | $10,673.25 |
DisclosureSEC source: 0001209191-21-067229 · doc4.xml · nonDerivative · entry 2 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Robert Erik Holmlin Traditional IRA Disclosed balance after: 4,875 Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 11:00 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 2,200 | $3.99 | $8,767.00 |
DisclosureSEC source: 0001209191-21-067229 · doc4.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Robert Erik Holmlin Traditional IRA Disclosed balance after: 2,200 Read SEC document |
| May 12, 2021 Filed May 14, 2021 23:16 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 290,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032934 · doc4.xml · nonDerivative · entry 2 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,191 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. Read SEC document |
| May 12, 2021 Filed May 14, 2021 23:16 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 290,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032934 · doc4.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,191 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes: 218 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on December 10, 2018, 450 shares acquired under the ESPP on June 10, 2019, 728 shares acquired under the ESPP on December 10, 2019, 1,014 shares acquired under the ESPP on June 10, 2020 and 1,151 shares acquired under the ESPP on December 10, 2020. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:32 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 775,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024789 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 Underlying: Common Stock · 775,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 00:23 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 290,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-20-011297 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 18, 2020 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2020 19:06 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001209191-20-016870 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:28 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 256,540 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053807 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,540 Underlying: Common Stock · 256,540 shares Expires 2028-09-30 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:53 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 1,630 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0001209191-18-048559 · doc4.xml · derivative · entry 2 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630 Underlying: Common Stock · 1,630 shares Expires 2023-08-21 F1 · price: Units purchased in the Issuer's Initial Public Offering for $6.125 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. F2 · derivative.exercise_date: 9/21/18 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:53 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 1,630 | $6.13 | $9,983.75 |
DisclosureSEC source: 0001209191-18-048559 · doc4.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630 F1 · price: Units purchased in the Issuer's Initial Public Offering for $6.125 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.